RxDoctor Payments Data

Karena Neri, MD

Internal Medicine · Palm Harbor, FLNPI 1730146259

Payments from drug & device makers

$1,011in general payments, 2019–2025

Across 43 payments — averaging $23.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$306
  • Esperion Therapeutics, Inc.$124
  • Pfizer$92
  • Novo Nordisk$82
  • Amarin Pharma, Inc.$66
  • Portola Pharmaceuticals, LLC$58
  • plus $282 from 13 others

What the payments were for

  • Food & beverage$1,011100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,011 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$264,662
Medicare patients
551
Services billed
2,997

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate123$131,481
XareltoRivaroxaban71$76,256
EliquisApixaban51$64,892
TrulicityDulaglutide18$29,474
FarxigaDapagliflozin Propanediol25$16,617
Janumet XrSitagliptin Phos/Metformin Hcl15$11,029
Levothyroxine Sodium877$9,035
SynthroidLevothyroxine Sodium117$8,760
JanumetSitagliptin Phos/Metformin Hcl15$8,399
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,137
Atorvastatin Calcium486$5,062
Rosuvastatin Calcium437$4,447
Albuterol Sulfate HfaAlbuterol Sulfate140$4,230
Pantoprazole Sodium281$3,873
Omeprazole231$3,607

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet Xr, Janumet$29$150,909153 claims
Johnson & JohnsonXarelto$15$76,25671 claims
PfizerEliquis, Paxlovid$92$67,75188 claims
AstraZenecaFarxiga, Symbicort$35$19,52236 claims
AbbVieSynthroid$306$8,760117 claims
GSKTrelegy Ellipta$36$7,13711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Palm Harbor

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →